Published in Mol Cell Biol on November 01, 2003
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol (2012) 1.74
Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol (2008) 1.42
What do drug transporters really do? Nat Rev Drug Discov (2014) 1.41
The Air noncoding RNA: an imprinted cis-silencing transcript. Cold Spring Harb Symp Quant Biol (2004) 1.27
Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol Pharmacol (2011) 1.16
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15
Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx (2005) 1.11
Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol (2011) 1.11
Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int (2013) 1.06
Drug transporters, the blood-testis barrier, and spermatogenesis. J Endocrinol (2010) 1.05
Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J (2013) 1.04
A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol (2012) 1.02
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res (2010) 1.01
Regulation of organic cation transport. Pflugers Arch (2004) 0.98
Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res (2006) 0.96
Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J (2013) 0.95
The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol (2014) 0.91
Extra-embryonic-specific imprinted expression is restricted to defined lineages in the post-implantation embryo. Dev Biol (2011) 0.89
Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. Mol Pharmacol (2015) 0.89
Characterization of the disposition and toxicokinetics of N-butylpyridinium chloride in male F-344 rats and female B6C3F1 mice and its transport by organic cation transporter 2. Drug Metab Dispos (2009) 0.88
Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev (2010) 0.88
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. Int J Mol Sci (2015) 0.86
Organic anion and cation SLC22 "drug" transporter (Oat1, Oat3, and Oct1) regulation during development and maturation of the kidney proximal tubule. PLoS One (2012) 0.84
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A (2015) 0.84
Expression and analysis of two novel rat organic cation transporter homologs, SLC22A17 and SLC22A23. Mol Cell Biochem (2011) 0.83
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res (2013) 0.82
Mechanisms underlying early rapid increases in creatinine in paraquat poisoning. PLoS One (2015) 0.82
Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res (2010) 0.81
Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling. Mol Psychiatry (2014) 0.81
Organic anion transporter 3 inhibitors as potential novel antihypertensives. Pharmacol Res (2008) 0.79
Properties and regulation of organic cation transport in freshly isolated mouse proximal tubules analyzed with a fluorescence reader-based method. Pflugers Arch (2011) 0.79
Transport of organic anions and cations in murine embryonic kidney development and in serially-reaggregated engineered kidneys. Sci Rep (2015) 0.78
Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. Drug Metab Dispos (2011) 0.77
The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch (2013) 0.77
Multispecific Organic Cation Transporter 1 (OCT1) from Bos taurus Has High Affinity and Slow Binding Kinetics towards Prostaglandin E2. PLoS One (2016) 0.77
Mouse organic cation transporter 1 determines properties and regulation of basolateral organic cation transport in renal proximal tubules. Pflugers Arch (2014) 0.76
The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol (2016) 0.75
Renal PET-imaging with (11)C-metformin in a transgenic mouse model for chronic kidney disease. EJNMMI Res (2016) 0.75
Activation of liver X receptor inhibits OCT2-mediated organic cation transport in renal proximal tubular cells. Pflugers Arch (2017) 0.75
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature (2002) 5.62
A physical map of the mouse genome. Nature (2002) 4.97
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med (1992) 2.22
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem (2002) 1.87
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol (2001) 1.83
Drug excretion mediated by a new prototype of polyspecific transporter. Nature (1994) 1.77
Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci (1998) 1.70
Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun (1996) 1.61
cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun (1998) 1.59
Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem (1998) 1.59
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 1.57
Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol (1999) 1.47
Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol (1998) 1.44
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem (1998) 1.42
Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol (2003) 1.39
Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol (2001) 1.37
Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics (2002) 1.34
Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem (1998) 1.31
Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther (1998) 1.29
Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol (2000) 1.29
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem (1996) 1.08
Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol (1998) 1.08
Secretion of tetraethylammonium by proximal tubules of rabbit kidneys. Am J Physiol (1983) 1.06
The Lx1 gene maps to mouse chromosome 17 and codes for a protein that is homologous to glucose and polyspecific transmembrane transporters. Mamm Genome (1996) 1.03
Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun (1998) 0.99
Molecular and functional characteristics of cloned human organic cation transporters. Pharm Biotechnol (1999) 0.94
Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.91
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res (2001) 0.85
Renal secretion of purine nucleosides and their analogs in mice. Biochem Pharmacol (1983) 0.83
The secretion of organic acids and bases by the ovine fetal kidney. Exp Physiol (1990) 0.82
Renal tubular secretion and reabsorption of organic bases in the dog. J Clin Invest (1962) 0.82
Intraspecies allometry: correlation between kidney weight and glomerular filtration rate vs. body weight. Am J Physiol (1982) 0.81
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest (2012) 2.33
The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med (2005) 2.01
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS (2002) 1.84
Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther (2003) 1.78
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells (2005) 1.46
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res (2009) 1.42
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer (2011) 1.40
Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev (2008) 1.39
Does modulation of organic cation transporters improve pralidoxime activity in an animal model of organophosphate poisoning? Crit Care Med (2011) 1.39
Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol (2003) 1.39
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest (2010) 1.37
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res (2002) 1.30
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol (2006) 1.29
Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther (2002) 1.28
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer (2005) 1.27
Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther (2004) 1.24
The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci (2005) 1.22
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther (2010) 1.21
The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol (2005) 1.20
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res (2003) 1.17
Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos (2008) 1.13
Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol (2005) 1.11
Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos (2006) 1.11
Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res (2012) 1.08
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res (2008) 1.07
Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci (2011) 1.07
Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem (2003) 1.07
Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos (2008) 1.06
P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother (2004) 1.06
Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res (2009) 1.05
Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther (2004) 1.03
High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res (2010) 1.03
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos (2005) 1.02
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res (2003) 1.01
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res (2009) 1.01
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res (2006) 1.00
Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J Exp Med (2005) 0.99
Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv (2009) 0.99
P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest (2013) 0.97
Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol (2007) 0.97
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res (2009) 0.96
Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res (2006) 0.96
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm (2012) 0.95
Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis (2005) 0.93
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos (2009) 0.93
P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer (2012) 0.93
Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm (2011) 0.93
Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol (2007) 0.93
Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol (2008) 0.92
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer (2013) 0.92
Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther (2009) 0.92
Recent advances in molecular pharmacology of the histamine systems: organic cation transporters as a histamine transporter and histamine metabolism. J Pharmacol Sci (2006) 0.92
Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol (2005) 0.91
Role of acetylcholine and muscarinic receptors in serotonin-induced bronchoconstriction in the mouse. J Mol Neurosci (2006) 0.91
Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos (2011) 0.91
P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther (2011) 0.91
A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev (2011) 0.90
P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob Agents Chemother (2008) 0.90
Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos (2005) 0.89
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther (2012) 0.89